The U.S. Court of Appeals for the Federal Circuit recently issued an en banc decision upholding an earlier ruling that patent applications must contain a specific “written description” of the claimed invention in addition to enabling language explaining how to make and use the invention.

The court’s decision Monday in Ariad Pharmaceuticals Inc. v. Eli Lilly and Co., which includes two separate dissenting-in-part and concurring-in-part opinions and a concurring opinion, upheld the court’s April 3, 2009, panel ruling. Circuit Judge Pauline Newman joined the majority opinion but submitted additional views.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]